XML 30 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 12 Months Ended 184 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2011
Cash flows from (used in): Operating activities:      
Net income/(loss) $ 4,685 $ (7,823) $ (103,971)
Adjustments for non-cash items:      
(Gain)/loss on derivative warrant (8,071) 3,251 (4,820)
Depreciation and amortization     1,404
Non-cash Cadherin Biomedical Inc. litigation expense     1,187
Unrealized foreign exchange loss (9) 36 36
Loss on impairment of capital assets     386
Amortization of and gain on lease inducements     (412)
Non-cash severance expense     168
Stock options issued to consultants 121 53 896
Stock options issued to employees 129 2,439 10,095
Acquired in-process research and development     13,094
Changes in working capital (81) 116 (104)
Net cash used in operating activities (3,226) (1,928) (82,043)
Investing activities:      
Purchase of capital assets     (1,440)
Disposal of capital assets     115
Proceeds from sale of assets     24
Release of restricted cash     190
Restricted cash     (209)
Purchase of short-term investments     (22,148)
Redemption of short-term investments     22,791
Investment in Cadherin Biomedical Inc.     (166)
Acquired intellectual property rights     (640)
Net cash provided (used) in investing activities     (1,483)
Financing activities:      
Conversion of long-term debt to equity     68
Long-term debt repayments     (65)
Capital lease repayments     (8)
Issuance of common stock 2,566 7,190 86,443
Registration expense     (465)
Financing expenses     (544)
Proceeds from convertible note     3,017
Other liability repayments     (87)
Security deposits received     35
Proceeds from exercise of stock options     51
Net cash provided from financing activities 2,566 7,190 88,445
Effect of exchange rate changes on cash and cash equivalents 10   378
Net change in cash and cash equivalents (650) 5,262 5,297
Cash and cash equivalents - Beginning of period 5,947 685  
Cash and cash equivalents - End of period $ 5,297 $ 5,947 $ 5,297